Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Use and Tolerability of Imatinib Mesylate (Gleevec) in Leukemia Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT00386373
First received: October 9, 2006
Last updated: July 31, 2012
Last verified: July 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: October 2007
  Primary Completion Date: October 2007 (Final data collection date for primary outcome measure)